Identifying CYP2D6 intermediate and poor metabolizers among schizophrenic patients with respect to therapeutical response.

JUŘICA, Jan, Richard BARTEČEK, Ondřej ZENDULKA, Tomáš KAŠPÁREK, Eva FLODROVÁ and Alexandra ŠULCOVÁ. Identifying CYP2D6 intermediate and poor metabolizers among schizophrenic patients with respect to therapeutical response. In Healthcare, 14, supp.1s. 25-25. 2010. ISSN 1365-1501.

Basic information

• Original name: Identifying CYP2D6 intermediate and poor metabolizers among schizophrenic patients with respect to therapeutical response.
• Name in Czech: Sledování intermediárních a pomalých metabolizátorů CYP2D6 u pacientů se schizofrenií s ohledem na terapeutickou odpověď na léčbu.
• Authors: JUŘICA, Jan, Richard BARTEČEK, Ondřej ZENDULKA, Tomáš KAŠPÁREK, Eva FLODROVÁ and Alexandra ŠULCOVÁ.
• Edition: Healthcare, 14, supp.1s. 25-25, 2010.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30104 Pharmacology and pharmacy
• Country of publisher: United States of America
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 0.327
• Organization unit: Faculty of Medicine
• ISSN: 1365-1501
• UT WoS: 000283365600047
• Keywords (in Czech): CYP2D6, schizofrenie, risperidon, fenotyp, genotyp
• Keywords in English: CYP2D6, schiphrenia, risperidone, phenotype, genotype
• Tags: cytochrome P450, genetic polymorphism

Abstract

The study sumarizes the knowledge of the correlation of metabolic phenotype and genotype of CYP2D6 with the therapeutical response in first episode- schizphrenic patients treated with risperidone.

Abstract (in Czech)

Příspěvek podává přehled dosavadních poznatků o souvislosti fenotypu a genotypu CYP2D6 a rychlostí odpovědi na léčbu risperidonem u pacientů s první atakou schizofrenie.

Links

• MSM0021622404, plan (intention): Name: Vnitřní organizace a neurobiologické mechanismy funkčních systémů CNS

Investor: Ministry of Education, Youth and Sports of the CR, The internal organisation and neurobiological mechanisms of functional CNS systems under normal and pathological conditions.

• NS9676, research and development project: Name: Vliv farmakogenetických a farmakokinetických faktorů na účinnost a bezpečnost terapie prvních epizod schizofrenie

Investor: Ministry of Health of the CR